by palligoelme@gmail.com | Mar 12, 2025 | Clinical Trials
Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder cancer space and data from several clinical trials evaluating agents for bladder cancer. Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder...
by palligoelme@gmail.com | Mar 12, 2025 | Clinical Trials
/PRNewswire/ — Advarra, the market leader in regulatory review solutions and clinical research technology, today announced the launch of Oncology Research… /PRNewswire/ — Advarra, the market leader in regulatory review solutions and clinical...
by palligoelme@gmail.com | Mar 12, 2025 | Clinical Trials
/PRNewswire/ — QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that… /PRNewswire/ — QurAlis Corporation (“QurAlis”), a...
by palligoelme@gmail.com | Mar 12, 2025 | Clinical Trials
The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 weeks, according to the phase 1 randomised controlled trial. The drug, which works by blocking HIV from entering and multiplying in human...
by palligoelme@gmail.com | Mar 12, 2025 | Clinical Trials
The planned innovative Phase 2 study of RHB-2041 will be the first ever clinical study in Crohn’s Disease (CD) patients who are all MAP-positive, and will… The planned innovative Phase 2 study of RHB-2041 will be the first ever clinical study in...
